Akso Health (AHG) Non-Current Deffered Revenue (2019 - 2020)
Akso Health (AHG) reported Non-Current Deffered Revenue of $96228.0 for Q1 2020, down 49.34% on a YoY basis from $189958.0 in Q2 2019, and down 38.04% quarter-over-quarter from $155300.0 in Q3 2019.
Akso Health (AHG) Non-Current Deffered Revenue (2019 - 2020) Analysis & Trends
Akso Health has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $96228.0 in Q1 2020.
- For the quarter ending Q1 2020, Non-Current Deffered Revenue fell 49.34% year-over-year to $96228.0; the trailing twelve-month figure through Mar 2020 stood at $96228.0 (down 49.34% YoY), and the FY2020 full-year result was $96228.0, down 49.34% from the prior year.
- Non-Current Deffered Revenue for Q1 2020 stood at $96228.0, down from $155300.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $189958.0 in Q1 2019, with the low at $96228.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | - |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | - |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | - |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | - |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | - |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | - |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 1.06 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | - |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | - |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 96,228.00 |
| Sep 30, 2019 | 155,300.00 |
| Mar 31, 2019 | 189,958.00 |